Sanjivani Paranteral News

Sanjivani Parenteral Reports 14.5% Revenue Decline in Q2 FY26 Due to Export Market Disruptions

Sanjivani Parenteral Limited reported revenue of INR 15.5 crores in Q2 FY26, down 14.5% year-on-year, primarily due to external disruptions including local unrest in Nepal affecting INR 1 crore worth of orders and tighter FDA scrutiny in Latin America slowing clearances. The company expects to start booking revenue from its SPL Infusion venture in Q3 FY26, with management projecting 10% minimum growth for the full year and targeting INR 150 crores revenue next year including contributions from the new IV plant.

Sanjivani Parenteral Reports Decline in Q2 FY26 Performance

Sanjivani Parenteral Limited reported revenue from operations of INR 155.0 million for Q2 FY26, down 14.5% year-on-year, with EBITDA declining 25.7% to INR 24.1 million and PAT falling 28.6% to INR 16.4 million. The pharmaceutical company, which manufactures parenteral and oral solid products across multiple therapeutic areas, shared these results through an investor presentation highlighting performance for the quarter and half-year ended September 30, 2025.

Sanjivani Parenteral Reports Mixed Q2FY26 Results with 14.5% Revenue Decline

Sanjivani Parenteral Limited reported quarterly revenue decline of 14.5% YoY to Rs. 155.0 mn with PAT down 28.6% YoY to Rs. 16.4 mn, while maintaining EBITDA margin at 15.5%. The pharmaceutical company's injectables segment grew 2.4% YoY but oral segment declined 35.4% YoY due to shipment challenges, with exports contributing 81.6% of total revenue from core markets including CIS, Middle East Africa and Latin America.